Dozens of new obesity drugs are coming: these are the ones to watch (Nature)

The future of anti-obesity drugs is rapidly evolving, with over 100 new candidates in development. While semaglutide (Ozempic) and tirzepatide (Mounjaro) have revolutionized weight loss treatments, they come with side effects, muscle loss concerns, and variability in effectiveness. Researchers are now exploring next-generation drugs that target multiple pathways, such as GIP, glucagon, and amylin, to enhance fat loss while preserving muscle. Oral alternatives, monthly injectables, and metabolism-boosting therapies are also in the pipeline. The article gives insights on how these advancements could reshape obesity treatment in the coming years.